JP2020533295A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533295A5
JP2020533295A5 JP2020513594A JP2020513594A JP2020533295A5 JP 2020533295 A5 JP2020533295 A5 JP 2020533295A5 JP 2020513594 A JP2020513594 A JP 2020513594A JP 2020513594 A JP2020513594 A JP 2020513594A JP 2020533295 A5 JP2020533295 A5 JP 2020533295A5
Authority
JP
Japan
Prior art keywords
composition
mazindol
substance
treatment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020513594A
Other languages
English (en)
Japanese (ja)
Other versions
JP7593619B2 (ja
JP2020533295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/001138 external-priority patent/WO2019058172A1/en
Publication of JP2020533295A publication Critical patent/JP2020533295A/ja
Publication of JP2020533295A5 publication Critical patent/JP2020533295A5/ja
Application granted granted Critical
Publication of JP7593619B2 publication Critical patent/JP7593619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020513594A 2017-09-07 2018-09-06 ヘロイン依存症及び物質使用障害のためのマジンドール治療 Active JP7593619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555469P 2017-09-07 2017-09-07
US62/555,469 2017-09-07
PCT/IB2018/001138 WO2019058172A1 (en) 2017-09-07 2018-09-06 MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES

Publications (3)

Publication Number Publication Date
JP2020533295A JP2020533295A (ja) 2020-11-19
JP2020533295A5 true JP2020533295A5 (cg-RX-API-DMAC7.html) 2021-08-19
JP7593619B2 JP7593619B2 (ja) 2024-12-03

Family

ID=64316589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513594A Active JP7593619B2 (ja) 2017-09-07 2018-09-06 ヘロイン依存症及び物質使用障害のためのマジンドール治療

Country Status (9)

Country Link
US (1) US11596622B2 (cg-RX-API-DMAC7.html)
EP (1) EP3678661A1 (cg-RX-API-DMAC7.html)
JP (1) JP7593619B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200085730A (cg-RX-API-DMAC7.html)
CN (1) CN111343979A (cg-RX-API-DMAC7.html)
BR (1) BR112020004506A2 (cg-RX-API-DMAC7.html)
CA (1) CA3074054A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020002560A (cg-RX-API-DMAC7.html)
WO (1) WO2019058172A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217987A (en) 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
JP2010537990A (ja) 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
WO2011123496A1 (en) * 2010-03-31 2011-10-06 Supernus Pharmaceuticals, Inc. Formulations of mazindol
US9687445B2 (en) 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
JP6584745B2 (ja) 2014-04-09 2019-10-02 和久 前田 抗肥満薬の効果を向上させる組成物の製造方法。
AU2017230974B2 (en) 2016-03-09 2022-02-03 Nls-1 Pharma Ag A mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)

Similar Documents

Publication Publication Date Title
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP2009525343A5 (cg-RX-API-DMAC7.html)
JP2012533565A5 (cg-RX-API-DMAC7.html)
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
WO2017141104A8 (en) Method for inducing a sustained immune response
JP2013511507A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
JP2012502015A5 (cg-RX-API-DMAC7.html)
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
JP2011068653A5 (cg-RX-API-DMAC7.html)
JP2015523407A5 (cg-RX-API-DMAC7.html)
JP2005512995A5 (cg-RX-API-DMAC7.html)
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
JP2010510286A5 (cg-RX-API-DMAC7.html)
JP2014516942A5 (cg-RX-API-DMAC7.html)
JP2019515908A5 (cg-RX-API-DMAC7.html)
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2008543936A5 (cg-RX-API-DMAC7.html)
JP2015522630A5 (cg-RX-API-DMAC7.html)
JP2009280621A5 (cg-RX-API-DMAC7.html)
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
JP2018527305A5 (cg-RX-API-DMAC7.html)
JP2016530238A5 (cg-RX-API-DMAC7.html)
ME02474B (me) Terapijski režimi